Mabwell (Shanghai) Bioscience Co. Ltd. A (688062) fair value: what the stock is really worth
As of Sep 30, 2026: fair value of Mabwell (Shanghai) Bioscience Co. Ltd. A ¥3.94, price ¥27.04, upside -85.4%, quality 37 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Mabwell (Shanghai) Bioscience Co. Ltd. A for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
56‑month range ¥13.09 – ¥59.97 · fair‑value band ¥1.85 – ¥6.45 · the ¥27.04 price screens above the ¥3.94 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Mabwell (Shanghai) Bioscience Co. Ltd. A in your weekly email
Every Wednesday you see whether Mabwell (Shanghai) Bioscience Co. Ltd. A is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Mabwell (Shanghai) Bioscience Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacture, and commercialization of biological products for oncology, immunology, bone disorders, ophthalmology, hematology, and infectious diseases in China and internationally.
Show more
Mabwell (Shanghai) Bioscience Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacture, and commercialization of biological products for oncology, immunology, bone disorders, ophthalmology, hematology, and infectious diseases in China and internationally. The company offers MAIWEIJIAN for the treatment of giant cell tumor of bone; MALISHU for the treatment of postmenopausal women with osteoporosis; MAILISHENG, an albipagrastim alfa injection; and JUNMAIKANG, an autoimmune Adalimumab injection. It also provides oncology products, including 9MW2821, a Nectin-4 targeting drug candidate in the Phase III clinical trials for the treatment of cervical cancer; 7MW3711, a B7-H3 targeting ADC for the treatment of advanced malignant solid tumors; and 7MW4911, an ADC that targets CDH17. In addition, the company offers immunology products comprising 9MW1911, an anti-ST2 antibody that is in Phase I clinical trial for the treatment of COPD, and 9MW3811, an anti-IL-11 antibody that is in Phase I clinical trial. Its bone disorder product pipeline consists of 1MW5011, an oral tablet for the treatment of osteoarthritis. Additionally, it provides ophthalmology products include 9MW0813, a recombinant VEGF receptor-antibody fusion protein for the treatment of ocular diseases related to vascularization; 9MW0211, a recombinant anti-VEGF humanized monoclonal antibody injection that is in Phase III clinical trials for the treatment of neovascularization-related eye diseases, such as neovascular age-related macular degeneration. Further, the company's hematology product comprises 9MW3011, a recombinant humanized anti-TMPRSS6 monoclonal antibody that is in Phase I clinical trials for the treatment of polycythemia vera and iron overload disorders, including beta-thalassemia. The company was founded in 2017 and is headquartered in Shanghai, China.
Stock analysis
Mabwell (Shanghai) Bioscience Co. Ltd. A (688062) currently trades at ¥27.04, while our model-based Fair Value estimate is ¥3.94, 85.4% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Dividend Discount group reads highest at a median of ¥2.97 per share, and 0 of the 3 models we run sit above the ¥27.04 price.
Bear case: the Asset-Based group reads lowest at ¥0.5900, and 3 of the 3 models stay below the price. Evidence for this calculation is low.
Scenario range: ¥1.85 (bear) to ¥6.45 (bull), the price of ¥27.04 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Mabwell (Shanghai) Bioscience Co. Ltd. A reported revenue of 663M CNY in FY2025 versus 16.2M CNY in FY2021, a compound +152.8%/yr. Reported net income was −970M CNY in FY2025.
Key figures
Market cap 13.8B CNY (≈ $2.1B) · P/S ratio 18.5 · EPS (TTM) ¥−2.31 · Dividend yield 0.6% · Net margin −146% · Return on equity −119% · Return on assets (EBIT) −27.6% · Operating margin −160%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).
What moves the price
The share trades about 45% below its 52-week high and 12% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −85%, 688062 screens richer than that median.
Fair Value models
Bear ¥1.85Fair Value ¥3.94Bull ¥6.45
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.30/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+231.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+188.0%
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+86.1%
’17
’18
’19
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−12,139.3% (2020) → −144.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Mabwell (Shanghai) Bioscience Co. Ltd. A with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 576 stocks
Beats the industry median on 2/10 measures
Overall it trails its industry peers.
Valuation
Quality Score37 · Below median
Fair Value upside−85.4% · Bottom 25%
Profitability
Return on assets−11.8% · Below median
Net margin (TTM)−123.4% · Bottom 25%
Operating margin (TTM)−160.5% · Bottom 25%
Growth and dividend
Revenue growth184.9% · Top 25%
Dividend yield (TTM)0.6% · Below median
Balance sheet
Debt / equity3.84× · Highest 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B5.90× · Priciest 25%
P/S (TTM)2.77× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)0· sector 97
DIVIDEND (yield)11· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Mabwell (Shanghai) Bioscience Co. Ltd. A Fair Value". https://www.fairvalue-calculator.com/stock/688062
Frequently asked questions
Is Mabwell (Shanghai) Bioscience Co. Ltd. A (688062) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ¥3.94 versus a price of ¥27.04, about −85% upside (overvalued).
What is the fair value of 688062?
Our model-based fair value for Mabwell (Shanghai) Bioscience Co. Ltd. A is ¥3.94 (as of Sep 24, 2026), built from audited fundamentals. The current price: ¥27.04.
What is the quality score of 688062?
Mabwell (Shanghai) Bioscience Co. Ltd. A has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Mabwell (Shanghai) Bioscience Co. Ltd. A (688062)?
Our model-based price target is the fair value of ¥3.94 (as of Sep 24, 2026) from 3 valuation models. Cautious scenario ¥1.85, optimistic scenario ¥6.45. It is a calculation from audited fundamentals, not an analyst target.
What is the Mabwell (Shanghai) Bioscience Co. Ltd. A stock forecast for 2026?
Our models put fair value at ¥3.94, about −85% upside versus a price of ¥27.04 (overvalued). Cautious scenario ¥1.85, optimistic scenario ¥6.45. The calculation is refreshed regularly with new filings.
What is the revenue of Mabwell (Shanghai) Bioscience Co. Ltd. A (688062)?
Mabwell (Shanghai) Bioscience Co. Ltd. A reported trailing-twelve-month revenue of about 745M CNY (latest available figure, as of Sep 24, 2026).
Does Mabwell (Shanghai) Bioscience Co. Ltd. A pay a dividend?
Mabwell (Shanghai) Bioscience Co. Ltd. A currently shows a dividend yield of about 0.57% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Mabwell (Shanghai) Bioscience Co. Ltd. A (688062)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Mabwell (Shanghai) Bioscience Co. Ltd. A it is ¥3.94 per share (as of Sep 24, 2026), against a price of ¥27.04. It is the blended result of 3 valuation models (cash flow, earnings, asset, dividend).
Is Mabwell (Shanghai) Bioscience Co. Ltd. A stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 688062 trades above its calculated fair value: price ¥27.04, fair value ¥3.94, a gap of about −85% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 688062?
No. The price is what the market pays today (¥27.04); the fair value is what the company's own numbers justify (¥3.94). For Mabwell (Shanghai) Bioscience Co. Ltd. A the two are ¥23.10 per share apart. That gap is exactly why we show both numbers side by side.
How much is Mabwell (Shanghai) Bioscience Co. Ltd. A worth?
The market values Mabwell (Shanghai) Bioscience Co. Ltd. A at about 13.8B CNY (market capitalisation, as of Sep 24, 2026). Per share that is ¥27.04; our models calculate a fair value of ¥3.94 per share.
What do the bullish and bearish scenarios say about 688062?
Our models span a range for Mabwell (Shanghai) Bioscience Co. Ltd. A: cautious scenario ¥1.85, base ¥3.94, optimistic ¥6.45 per share (as of Sep 24, 2026, price ¥27.04). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Mabwell (Shanghai) Bioscience Co. Ltd. A (688062)?
Balance-sheet figures for Mabwell (Shanghai) Bioscience Co. Ltd. A (as of Sep 24, 2026): return on equity −118.9%, debt of 3.84 per unit of equity. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is 688062 from its 52-week high?
Mabwell (Shanghai) Bioscience Co. Ltd. A trades at ¥27.04, about 45% below its 52-week high of ¥49.12 and 12% above the low of ¥24.06 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of ¥3.94 is for.
Which stocks are comparable to Mabwell (Shanghai) Bioscience Co. Ltd. A?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Mabwell (Shanghai) Bioscience Co. Ltd. A stock attractive at the current price?
The data as of Sep 24, 2026: price ¥27.04, calculated fair value ¥3.94 (−85%), Quality Score 37/100, from 3 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 688062 calculated?
We run Mabwell (Shanghai) Bioscience Co. Ltd. A through 3 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥3.94, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Mabwell (Shanghai) Bioscience Co. Ltd. A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Mabwell (Shanghai) Bioscience Co. Ltd. A (688062)?
The closing price on Sep 30, 2026 was ¥27.04. Our model-based fair value is ¥3.94, about −85% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Mabwell (Shanghai) Bioscience Co. Ltd. A right now?
The price sits above even our optimistic bull case (¥6.45). The favourable scenario is already priced in. Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts. The model range is unusually wide (¥1.85 to ¥6.45). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Mabwell (Shanghai) Bioscience Co. Ltd. A
How large is the market capitalisation of Mabwell (Shanghai) Bioscience Co. Ltd. A (688062)?
The market capitalisation of Mabwell (Shanghai) Bioscience Co. Ltd. A is 13.8B CNY (≈ $2.1B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Mabwell (Shanghai) Bioscience Co. Ltd. A (688062)?
The price-to-sales ratio of Mabwell (Shanghai) Bioscience Co. Ltd. A is 18.5 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Mabwell (Shanghai) Bioscience Co. Ltd. A (688062)?
Earnings per share at Mabwell (Shanghai) Bioscience Co. Ltd. A are ¥−2.31. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Mabwell (Shanghai) Bioscience Co. Ltd. A (688062)?
The dividend yield of Mabwell (Shanghai) Bioscience Co. Ltd. A is 0.6%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Mabwell (Shanghai) Bioscience Co. Ltd. A (688062)?
The net margin of Mabwell (Shanghai) Bioscience Co. Ltd. A is −146% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Mabwell (Shanghai) Bioscience Co. Ltd. A (688062)?
The return on equity (ROE) of Mabwell (Shanghai) Bioscience Co. Ltd. A is −119% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Mabwell (Shanghai) Bioscience Co. Ltd. A (688062)?
On an EBIT basis the return on assets of Mabwell (Shanghai) Bioscience Co. Ltd. A is −27.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Mabwell (Shanghai) Bioscience Co. Ltd. A (688062)?
The operating margin of Mabwell (Shanghai) Bioscience Co. Ltd. A is −160% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Mabwell (Shanghai) Bioscience Co. Ltd. A (688062)?
Revenue at Mabwell (Shanghai) Bioscience Co. Ltd. A is growing +185% versus a year earlier (3y avg +188%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Mabwell (Shanghai) Bioscience Co. Ltd. A (688062) generate?
The free cash flow of Mabwell (Shanghai) Bioscience Co. Ltd. A is −447M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Mabwell (Shanghai) Bioscience Co. Ltd. A (688062) carry?
The net debt of Mabwell (Shanghai) Bioscience Co. Ltd. A is 1.4B CNY (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Mabwell (Shanghai) Bioscience Co. Ltd. A in the live analysis
One click puts Mabwell (Shanghai) Bioscience Co. Ltd. A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
